BACKGROUND AND PURPOSE: We have performed a case-control study in 413 prostate cancer patients to test for association between TGFβ1 and the development of late normal-tissue toxicity among prostate cancer patients treated with three-dimensional conformational radiotherapy (3D-CRT) MATERIALS AND METHODS: Late gastrointestinal and genitourinary toxicities were assessed for at least two years after radiotherapy in 413 patients according to CTCAEvs3 scores. Codominant genotypic tests and haplotypic analyses were undertaken to evaluate the correlation between TGFβ1 SNPs rs1800469, rs1800470 and rs1800472 and radio-induced toxicity. RESULTS: Neither the SNPs nor the haplotypes were found to be associated with the risk of late toxicity. CONCLUSIONS: We were able to exclude up to a 2-fold increase in the risk of developing late gastrointestinal and genitourinary radio-induced toxicity due to the TGFβ1 SNPs rs1800469 and rs1800470, as well as the two most frequent TGFβ1 haplotypes.
BACKGROUND AND PURPOSE: We have performed a case-control study in 413 prostate cancerpatients to test for association between TGFβ1 and the development of late normal-tissue toxicity among prostate cancerpatients treated with three-dimensional conformational radiotherapy (3D-CRT) MATERIALS AND METHODS: Late gastrointestinal and genitourinary toxicities were assessed for at least two years after radiotherapy in 413 patients according to CTCAEvs3 scores. Codominant genotypic tests and haplotypic analyses were undertaken to evaluate the correlation between TGFβ1 SNPs rs1800469, rs1800470 and rs1800472 and radio-induced toxicity. RESULTS: Neither the SNPs nor the haplotypes were found to be associated with the risk of late toxicity. CONCLUSIONS: We were able to exclude up to a 2-fold increase in the risk of developing late gastrointestinal and genitourinary radio-induced toxicity due to the TGFβ1 SNPs rs1800469 and rs1800470, as well as the two most frequent TGFβ1 haplotypes.
Authors: Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den Journal: Nat Rev Urol Date: 2013-09-10 Impact factor: 14.432
Authors: Sarah L Kerns; Richard G Stock; Nelson N Stone; Seth R Blacksburg; Lynda Rath; Ana Vega; Laura Fachal; Antonio Gómez-Caamaño; Dirk De Ruysscher; Guido Lammering; Matthew Parliament; Michael Blackshaw; Michael Sia; Jamie Cesaretti; Mitchell Terk; Rosetta Hixson; Barry S Rosenstein; Harry Ostrer Journal: Radiother Oncol Date: 2013-05-26 Impact factor: 6.280
Authors: Laura Fachal; Antonio Gómez-Caamaño; Gillian C Barnett; Paula Peleteiro; Ana M Carballo; Patricia Calvo-Crespo; Sarah L Kerns; Manuel Sánchez-García; Ramón Lobato-Busto; Leila Dorling; Rebecca M Elliott; David P Dearnaley; Matthew R Sydes; Emma Hall; Neil G Burnet; Ángel Carracedo; Barry S Rosenstein; Catharine M L West; Alison M Dunning; Ana Vega Journal: Nat Genet Date: 2014-06-29 Impact factor: 38.330
Authors: Thomas Van den Broeck; Steven Joniau; Liesbeth Clinckemalie; Christine Helsen; Stefan Prekovic; Lien Spans; Lorenzo Tosco; Hendrik Van Poppel; Frank Claessens Journal: Biomed Res Int Date: 2014-02-19 Impact factor: 3.411
Authors: Mahbubl Ahmed; Leila Dorling; Sarah Kerns; Laura Fachal; Rebecca Elliott; Matt Partliament; Barry S Rosenstein; Ana Vega; Antonio Gómez-Caamaño; Gill Barnett; David P Dearnaley; Emma Hall; Matt Sydes; Neil Burnet; Paul D P Pharoah; Ros Eeles; Catharine M L West Journal: Br J Cancer Date: 2016-04-12 Impact factor: 7.640
Authors: Sarah L Kerns; Leila Dorling; Laura Fachal; Søren Bentzen; Paul D P Pharoah; Daniel R Barnes; Antonio Gómez-Caamaño; Ana M Carballo; David P Dearnaley; Paula Peleteiro; Sarah L Gulliford; Emma Hall; Kyriaki Michailidou; Ángel Carracedo; Michael Sia; Richard Stock; Nelson N Stone; Matthew R Sydes; Jonathan P Tyrer; Shahana Ahmed; Matthew Parliament; Harry Ostrer; Barry S Rosenstein; Ana Vega; Neil G Burnet; Alison M Dunning; Gillian C Barnett; Catharine M L West Journal: EBioMedicine Date: 2016-07-20 Impact factor: 8.143